Evidence map›Paper›PMID 29563200›Full record

ArticleJournal of clinical microbiology2018

Monitoring Shedding of Five Genotypes of RotaTeq Vaccine Viruses by Genotype-Specific Real-Time Reverse Transcription-PCR Assays.

Yuki Higashimoto, Masaru Ihira, Yu Miyazaki, Ayumi Kuboshiki, Sayaka Yoshinaga, Hiroyuki Hiramatsu, Ryota Suzuki, Masafumi Miyata, Hiroki Miura, Satoshi Komoto and 4 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of clinical microbiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Yuki HigashimotoFaculty of Medical Technology, Fujita Health University School of Health Sciences, Toyoake, Aichi, Japan.
Masaru IhiraFaculty of Clinical Engineering, Fujita Health University School of Health Sciences, Toyoake, Aichi, Japan.
Yu MiyazakiFaculty of Medical Technology, Fujita Health University School of Health Sciences, Toyoake, Aichi, Japan.
Ayumi KuboshikiFaculty of Medical Technology, Fujita Health University School of Health Sciences, Toyoake, Aichi, Japan.
Sayaka YoshinagaFaculty of Medical Technology, Fujita Health University School of Health Sciences, Toyoake, Aichi, Japan.
Hiroyuki HiramatsuDepartment of Clinical Pharmacy, Fujita Health University Hospital, Toyoake, Aichi, Japan.
Ryota SuzukiDepartment of Clinical Pharmacy, Fujita Health University Hospital, Toyoake, Aichi, Japan.
Masafumi MiyataDepartment of Pediatrics, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.
Hiroki MiuraDepartment of Pediatrics, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.
Satoshi KomotoVirology and Parasitology, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.
Jun YukitakeFaculty of Medical Technology, Fujita Health University School of Health Sciences, Toyoake, Aichi, Japan.
Koki TaniguchiVirology and Parasitology, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.
Yoshiki KawamuraDepartment of Pediatrics, Fujita Health University School of Medicine, Toyoake, Aichi, Japan kyoshiki3@hotmail.com.
Tetsushi YoshikawaDepartment of Pediatrics, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.
Fujita Health University · JPFujita Health University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

RotaTeq (RV5) is a widely used live attenuated pentavalent rotavirus (RV) vaccine. Although fecal shedding of RV vaccine strains persists for long time periods, it is unclear how each vaccine strain replicates in intestinal tissue and is excreted in stool. To examine this issue, we established RV5 genotype-specific real-time reverse transcription-PCR (RT-PCR) assays. Five real-time RT-PCR assays were designed for the VP7 gene in genotypes G1, G2, G3, G4, and G6. All assays exhibited excellent linearity, and the detection limit was 1 infectious unit (IU)/reaction for G2, G4, and G6 and 10 IUs/reaction for G1 and G3. No cross-reactivity was observed among G genotypes. The inter- and intra-assay coefficients of variation were less than 3%. The assays were used to examine 129 stool samples collected from eight infants who received RV5. In cases 1 and 2, who received three rounds of vaccination, RV shedding decreased gradually with the number of vaccinations. G1 and G6 shedding appeared to be predominant in comparison to shedding of the other genotypes. Patterns of fecal shedding of the five genotypes of vaccine viruses differed between the eight vaccine recipients. RV5 genotype-specific real-time RT-PCR assays will be useful to study the molecular biology of RV5 replication in infants and experimental animals.

Indexed as

GenotypeVirus SheddingAntigens, ViralCapsid ProteinsFecesHumansInfantIntestinesLimit of DetectionReal-Time Polymerase Chain ReactionRNA, ViralRotavirusRotavirus InfectionsRotavirus VaccinesSensitivity and SpecificityVaccines, AttenuatedAntigens, ViralCapsid ProteinsRNA, ViralRotaTeqRotavirus VaccinesVaccines, AttenuatedVP7 protein, Rotavirusgenotypehuman rotavirusreal-time RT-PCRRotaTeqrotavirus vaccineshedding

Identifiers

PMID29563200
PMCPMC5971533
OpenAlexW2793195249

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.